Zombie Aqua™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye, Dead, Apoptosis
Ave. Rating
Submit a Review
Product Citations
publications
1-Zombie_Aqua_Viability_Dye_nowash_050713
One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • 1-Zombie_Aqua_Viability_Dye_nowash_050713
    One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • b-Zombie_Aqua_Viability_Dye_032713
    One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • c-Zombie_Aqua_Viability_Dye_012721
    HeLa cells were treated with 20% EtOH for 20 seconds, washed twice with PBS, and then were left to recover for five minutes with cell culture media in 37°C. The cells were stained with Zombie Aqua™ (1:1000) (cyan) for 15 minutes and then fixed with 1% paraformaldehyde (PFA) for ten minutes. Nuclei were counterstained with DRAQ5 (Red) for five minutes. The image was captured with 40X objective.
See Zombie Aqua™ spectral data
Cat # Size Price Quantity Check Availability Save
423101 100 tests $89
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423102 500 tests $335
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie Aqua™ is an amine-reactive fluorescent dye that is non-permeant to live cells but permeant to cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie Aqua™ is a polar, water-soluble dye providing very bright green fluorescence, making it suitable for use in multi-color detection.
 

Product Details
Technical data sheet

Product Details

Preparation
Zombie Aqua™ Fixable Viability Kit is composed of lyophilized Zombie Aqua™ dye and anhydrous DMSO. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved. 100 tests = 1 vial of Zombie Aqua™ + DMSO, 500 tests = 5 vials of Zombie Aqua™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie Aqua™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC, ICFC - Quality tested
ICC - Verified

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. For immunofluorescence microscopy, the suggested dilution is 1:1000. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

 

Excitation Laser
Violet Laser (405 nm)
Application Notes

Zombie Aqua™ dye is excited by the violet laser and has a maximum emission of 516 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie Aqua™ dye has similar emission to Brilliant Violet 510™.

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie Aqua™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie Aqua™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  5. Incubate the cells at room temperature (or 4°C), in the dark, for 15-30 minutes.
  6. Wash one time with 2 mL BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

No-wash Sequential Staining Protocol:

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie Aqua™ dye and mix until fully  dissolved
  3. Determine the total µL volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µl total staining volume intended for the assay. In the remaining volume, dilute Zombie Aqua™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µL total staining volume, use 80 µL of Zombie Aqua™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie Aqua™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  4. Incubate for 10-15 minutes at RT (or 4°C), protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.
    • Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie Aqua™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie Aqua™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie Aqua™.
Additional Product Notes

View more applications data using this product to validate Veri-Cells™ lyophilized control cells and to study dendritic cell subsets.

Application References

(PubMed link indicates BioLegend citation)
  1. Vom Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  2. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  3. Price PJ, et al. 2014. J Virol. 88:10840. PubMed
  4. Schmid MA, et al. 2014. PLoS Pathog. 10:1004541. PubMed
  5. Cohen SB, et al. 2015. J Immunol. 194:210. PubMed
  6. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  7. Price PJ, et al. 2015. J Immunol. 194:1164. PubMed
  8. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  9. Tzeng A, et al. 2015. PNAS. 112:3320. PubMed
  10. Peres AG, et al. 2015. Infect Immun. 83:1587. PubMed
  11. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
Product Citations
  1. Bussières-Marmen S, et al. 2017. Cell Mol Immunol. 10.1038/cmi.2016.72. PubMed
  2. Darzianiazizi M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  3. Soon MSF, et al. 2020. Nat Immunol. 1.984027778. PubMed
  4. Lindner SE, et al. 2020. Immunohorizons. 0.356944444. PubMed
  5. Tasker C, et al. 2021. AAPS J. 23:26. PubMed
  6. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  7. Kim J, et al. 2021. Front Cell Neurosci. 638098:15. PubMed
  8. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  9. Rueschenbaum S, et al. 2021. Front Immunol. 11:581352. PubMed
  10. Fantone K, et al. 2021. Pathogens. 10:. PubMed
  11. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
  12. Eiva MA, et al. 2022. Eur J Immunol. 52:96. PubMed
  13. Duraiswamy J, et al. 2021. Cancer Cell. 39:1623. PubMed
  14. Herz J, et al. 2021. Neuron. 109:3609. PubMed
  15. Mills EL, et al. 2022. Cell Metab. 34:140. PubMed
  16. Miek L, et al. 2022. Immunology. 166:47. PubMed
  17. Wolf B, et al. 2022. Immunology. 166:380. PubMed
  18. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  19. Shcheynikov N, et al. 2022. Hepatology. 76:1248. PubMed
  20. Tang Q, et al. 2022. Mol Ther. 30:2709. PubMed
  21. Adam-Artigues A, et al. 2022. Sci Adv. 8:eabk2746. PubMed
  22. Yang K, et al. 2022. Sci Immunol. 7:eabn2888. PubMed
  23. Sugimoto S, et al. 2022. Nat Metab. 4:775. PubMed
  24. Ma T, et al. 2022. Elife. 11: . PubMed
  25. Benedetti V, et al. 2022. Sci Adv. 8:eabn3986. PubMed
  26. Guasconi L, et al. 2022. J Fungi (Basel). 8: . PubMed
  27. Zhu J, et al. 2022. Research (Wash D C). 2022:9816272. PubMed
  28. Shen Z, et al. 2022. EBioMedicine. 85:104285. PubMed
  29. Martínez-Sabadell A, et al. 2022. Cell Rep. 41:111430. PubMed
  30. Gao Y, et al. 2022. Cell Res. 32:1086. PubMed
  31. Dhar R, et al. 2022. Int J Mol Med. 50: . PubMed
  32. Balood M, et al. 2022. Nature. 611:405. PubMed
  33. Yoo HJ, et al. 2022. Cell Rep. 41:111598. PubMed
  34. Liang Y, et al. 2022. Theranostics. 12:7729. PubMed
  35. Rico-Llanos G, et al. 2022. Front Immunol. 13:1054962. PubMed
  36. Chen W, et al. 2022. Front Immunol. 13:1046426. PubMed
  37. Zia S, et al. 2022. Mol Neurodegener. 17:82. PubMed
  38. Zhuang L, et al. 2022. J Am Heart Assoc. 11:e027228. PubMed
  39. Pleuger C, et al. 2022. Elife. 11: . PubMed
  40. Shen W, et al. 2023. Dis Model Mech. 16: . PubMed
  41. Perveen R, et al. 2023. Hum Cell. 36:583. PubMed
  42. Krammer S, et al. 2022. Cells. 12: . PubMed
  43. Chan L, et al. 2022. Cells. 12: . PubMed
  44. Cousin N, et al. 2022. Cells. 12: . PubMed
  45. Rice CM, et al. 2023. Life Sci Alliance. 6: . PubMed
  46. Zhao Q, et al. 2023. Nutrients. 15: . PubMed
  47. Romine KA, et al. 2023. Leukemia. 37:580. PubMed
  48. Ai L, et al. 2023. Cell Discov. 9:9. PubMed
  49. Gong HH, et al. 2023. Front Immunol. 13:1089064. PubMed
  50. Gonçalves R, et al. 2023. iScience. 26:105972. PubMed
  51. Liu G, et al. 2023. Commun Biol. 6:102. PubMed
  52. Li H, et al. 2023. Front Immunol. 13:1056447. PubMed
  53. Lutz EA, et al. 2022. PNAS Nexus. 1:pgac244. PubMed
  54. Badenes M, et al. 2023. Life Sci Alliance. 6: . PubMed
  55. Pušnik J, et al. 2023. Nat Commun. 14:572. PubMed
  56. Kang J, et al. 2023. JCI Insight. 8: . PubMed
  57. Chan L, et al. 2023. Int J Mol Sci. 24: . PubMed
  58. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  59. Drummer C, et al. 2023. Front Immunol. 14:1113883. PubMed
  60. Li Y, et al. 2022. Brain Behav Immun. 101:1. PubMed
  61. Ryan CB, et al. 2022. Neurobiol Dis. 163:105608. PubMed
  62. Fahrner JE, et al. 2022. Cancer Discov. 12:958. PubMed
  63. Blair TC, et al. 2022. Life Sci Alliance. 5:. PubMed
  64. Ko J, et al. 2022. Nat Biotechnol. 40:1654. PubMed
  65. Zhu Z, et al. 2022. Clin Cancer Res. 28:4820. PubMed
  66. Lutz EA, et al. 2022. Proc Natl Acad Sci U S A. 119:e2205983119. PubMed
  67. Bermea KC, et al. 2022. J Vis Exp. . PubMed
  68. Jia L, et al. 2022. Gut Microbes. 14:2117503. PubMed
  69. Frost JN, et al. 2022. Sci Adv. 8:eabq5384. PubMed
  70. Schuhmacher J, et al. 2022. Cells. 11:. PubMed
  71. Cruz-Reséndiz A, et al. 2022. Front Immunol. 13:1057499. PubMed
  72. Johnson SD, et al. 2022. Front Immunol. 13:1001727. PubMed
  73. Egli J, et al. 2022. MAbs. 14:2143009. PubMed
  74. Lao L, et al. 2023. Cancer Immunol Res. 11:320. PubMed
  75. Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed
  76. Yang Y, et al. 2023. MBio. 14:e0328522. PubMed
  77. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  78. Jun SH, et al. 2023. Nat Commun. 14:982. PubMed
  79. Fernandes S, et al. 2023. iScience. 26:106071. PubMed
  80. Aso K, et al. 2023. Nat Commun. 14:984. PubMed
  81. Medina S, et al. 2023. Water (Basel). 15:. PubMed
  82. Gupta T, et al. 2023. Front Immunol. 14:1044703. PubMed
  83. Xu K, et al. 2023. Elife. 12:. PubMed
  84. Battistello E, et al. 2023. Mol Cell. 83:1216. PubMed
  85. Zhang J, et al. 2023. Front Immunol. 14:1091541. PubMed
  86. Harpur CM, et al. 2023. Clin Transl Immunology. 12:e1443. PubMed
  87. Pankhurst TE, et al. 2023. Cell Rep. 42:112310. PubMed
  88. Ahmed O, et al. 2023. Bioelectron Med. 9:6. PubMed
  89. Freitag PC, et al. 2023. Mol Ther Methods Clin Dev. 29:120. PubMed
  90. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  91. Madar J, et al. 2023. Nat Commun. 14:2158. PubMed
  92. Consonni FM, et al. 2023. Front Immunol. 14:1168455. PubMed
  93. Fang Y, et al. 2023. Front Immunol. 14:1162004. PubMed
  94. Chaturvedi S, et al. 2023. Cell. 186:2036. PubMed
  95. Ximerakis M, et al. 2023. Nat Aging. 3:327. PubMed
  96. Liao Y, et al. 2023. ACS Omega. 8:15217. PubMed
  97. Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed
  98. Liu JC, et al. 2023. Int J Mol Sci. 24:. PubMed
  99. Tang L, et al. 2023. Front Immunol. 14:1145441. PubMed
  100. Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed
  101. Malik JR, et al. 2023. Int J Mol Sci. 24:. PubMed
  102. Feng X, et al. 2023. Nat Commun. 14:3208. PubMed
  103. Komoto S, et al. 2023. Cancers (Basel). 15:. PubMed
  104. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  105. Mo Y, et al. 2022. Front Immunol. 12:799896. PubMed
  106. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  107. Castle AR, et al. 2022. PLoS One. 17:e0269342. PubMed
  108. Healy LM, et al. 2020. Glia. 68:811. PubMed
  109. Buchanan MW, et al. 2021. J Orthop Res. 39:1710. PubMed
  110. Nuccitelli R, et al. 2017. J Immunother Cancer . 10.1186/s40425-017-0234-5. PubMed
  111. Kaczanowska S, et al. 2017. Cancer Res. . 10.1158/0008-5472.CAN-17-0653. PubMed
  112. Gálvez-Cancino F, et al. 2018. Oncoimmunology. 7:e1442163. PubMed
  113. Contijoch EJ et al. 2019. eLife. 8 pii: e40553. PubMed
  114. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  115. Seki SM, et al. 2020. Sci Signal. :13. PubMed
  116. Krausgruber T, et al. 2020. Nature. 583:296. PubMed
  117. Fujii H, et al. 2015. PLoS One. 10: 0133216. PubMed
  118. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  119. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  120. Lam B, et al. 2021. Cell Rep. 37:109838. PubMed
  121. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  122. Chaturvedi S, et al. 2022. Cell. 185:2086. PubMed
  123. Volta V, et al. 2021. Nat Commun. 12:6979. PubMed
  124. Böttcher M, et al. 2018. Oncoimmunology. 7:e1445454. PubMed
  125. Jeevan-Raj B, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.071. PubMed
  126. Lownik JC, et al. 2020. Biochem Biophys Res Commun. 522:442. PubMed
  127. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  128. Price P, et al. 2014. J Virol. 88:10840. PubMed
  129. Tzeng A, et al. 2015. Proc Natl Acad Sci U S A. 112:3320. PubMed
  130. Yamaguchi M, et al. 2016. J Leukoc Biol. 100: 131 - 141. PubMed
  131. Swee L, et al. 2016. Open Bio. 6: 160293. PubMed
  132. Shin HS, et al. 2022. Sci Rep. 12:17605. PubMed
  133. Meyer Zu Natrup C, et al. 2022. J Clin Invest. Online ahead of print. PubMed
  134. Toomer G, et al. 2022. Viruses. 14:. PubMed
  135. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
  136. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  137. Blake SJ, et al. 2021. Cell Rep Med. 2:100464. PubMed
  138. Lo MW, et al. 2022. Clin Transl Immunology. 11:e1413. PubMed
  139. Gálvez-Cancino F, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.041. PubMed
  140. Bailey S, et al. 2017. Nat Commun.. 10.1038/s41467-017-01867-9. PubMed
  141. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  142. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  143. Deng X, et al. 2021. Open Biol. 11:200340. PubMed
  144. Yu X, et al. 2021. Nature. 594:560. PubMed
  145. Park JJ, et al. 2021. Nat Commun. 12:1222. PubMed
  146. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  147. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
  148. Li LH, et al. 2020. Antiviral Res. 104929:183. PubMed
  149. Jenull S, et al. 2021. Cell Reports. 36(3):109406. PubMed
  150. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  151. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  152. Neidleman J, et al. 2020. Elife. 9:00. PubMed
  153. Alberts-Grill N, et al. 2016. J Immunol. 197(12):4651-4662. PubMed
  154. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  155. Torre S, et al. 2016. Nat Immunol. 10.1038/ni.3581. PubMed
  156. Bittner-Eddy P, et al. 2016. J Immunol. 197: 1435 - 1446. PubMed
  157. Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  158. Setten E, et al. 2022. Nat Commun. 13:6499. PubMed
  159. Liu Y, et al. 2022. Cancer Discov. :. PubMed
  160. Imbrechts M, et al. 2022. iScience. 25:104705. PubMed
  161. Munoz MA, et al. 2021. Elife. 10:. PubMed
  162. Gong W, et al. 2021. Oncoimmunology. 10:1997385. PubMed
  163. Gu H, et al. 2021. Immun Inflamm Dis. 9:1686. PubMed
  164. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  165. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  166. Witkowski M, et al. 2021. Nature. 600:295. PubMed
  167. Meehan S, et al. 2019. Commun Biol. 2:229. PubMed
  168. Tan L, et al. 2019. Cell Rep. 27:3657. PubMed
  169. Hartsough EJ, et al. 2019. Cell Death Dis. 10:281. PubMed
  170. Chattopadhyay A, et al. 2018. Sci Rep. 8:9032. PubMed
  171. Martrus G, et al. 2017. PLoS One.. 10.1371/journal.pone.0182532. PubMed
  172. Hagen SH, et al. 2020. Cell Rep. 33:108485. PubMed
  173. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  174. Darzianiazizi M, et al. 2021. Cytokine X. 3:100053. PubMed
  175. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  176. Peres A, et al. 2015. Infect Immun . 83:1587. PubMed
  177. Yoshida N, et al. 2016. Nat Commun. 7: 12993. PubMed
  178. Fang V, et al. 2016. Nat Immunol. 18:15-25. PubMed
  179. Martínez-Sabadell A, et al. 2022. STAR Protoc. 3:101712. PubMed
  180. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  181. Mathur S, et al. 2021. JCI Insight. 6:. PubMed
  182. Pedersen JG, et al. 2021. Front Microbiol. 12:763030. PubMed
  183. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  184. Bresque M, et al. 2022. J Biol Chem. :101711. PubMed
  185. Peng Q, et al. 2022. EBioMedicine. 77:103904. PubMed
  186. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  187. Ruetsche D, et al. 2022. Cells. 11:. PubMed
  188. Wright AKA, et al. 2017. J Allergy Clin Immunol. 140:1430. PubMed
  189. Botuyan MV, et al. 2018. Nat Struct Mol Biol. 25:591. PubMed
  190. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  191. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  192. Amberg N, et al. 2016. J Invest Dermatol. 136:2140-2149. PubMed
  193. Cunningham C, et al. 2016. PLoS Pathog. 12: 1005356. PubMed
  194. Schmitt N, et al. 2015. Mol Cancer Ther. 14: 2103-2111. PubMed
  195. Chen Z, et al. 2022. Theranostics. 12:6242. PubMed
  196. Tang JJ, et al. 2022. Cell Rep. 39:110987. PubMed
  197. Luo X, et al. 2021. J Biol Chem. 297:101098. PubMed
  198. Johansen AZ, et al. 2022. Pharmaceutics. 14:. PubMed
  199. Rogawski DS, et al. 2021. Nat Commun. 12:2792. PubMed
  200. Britton GJ et al. 2019. Immunity. 50(1):212-224 . PubMed
  201. Grozio A, et al. 2019. Nat Metab. 1:47. PubMed
  202. Ramsey HE, et al. 2018. Cancer Discov. 8:1566. PubMed
  203. Parameswaran P, et al. 2017. Cell Host Microbe. 10.1016/j.chom.2017.08.003. PubMed
  204. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  205. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  206. Jordan PM, et al. 2020. Cell Rep. 33:108247. PubMed
  207. Doty DT, et al. 2020. Int J Mol Sci. 21:00. PubMed
  208. Dillon SM, et al. 2020. Bio Protoc. e3486:10. PubMed
  209. Pantelyushin S, et al. 2021. Cancers (Basel). :13. PubMed
  210. Alsaleh G, et al. 2020. Elife. 9: . PubMed
  211. Stuani L, et al. 2021. J Exp Med. 218:. PubMed
  212. Denkers S 2015. J Immunol. 195: 2754-2762. PubMed
  213. Garcia-Bates T, et al. 2016. J Immunol. 196: 2870 - 2878. PubMed
  214. Davidson S, et al. 2016. EMBO Mol Med. 8: 1099 - 1112. PubMed
  215. Alvisi G, et al. 2022. Methods Mol Biol. 2559:243. PubMed
  216. Li FJ, et al. 2022. PLoS One. 17:e0277019. PubMed
  217. Valbuena Perez JV, et al. 2020. Aging Cell. 19:e13156. PubMed
  218. Sellau J, et al. 2020. Nat Commun. 2.860416667. PubMed
  219. Zheng S, et al. 2022. Blood Cancer Discov. 3:103. PubMed
  220. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  221. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  222. Tang Y, et al. 2021. Cancer Discov. 11:3142. PubMed
  223. Borst L, et al. 2022. Int J Cancer. 150:688. PubMed
  224. Ceholski D, et al. 2017. Stem Cell Res. 10.1016/j.scr.2017.06.015. PubMed
  225. Metzemaekers M, et al. 2017. Int J Mol Sci. 10.3390/ijms18071513. PubMed
  226. Tien S, et al. 2017. PLoS One. 10.1371/journal.pone.0181338. PubMed
  227. Karagianni AE, et al. 2021. Sci Rep. 11:14292. PubMed
  228. Korangath P, et al. 2020. Bio Protoc. 10:e3822. PubMed
  229. Amanat F, et al. 2021. Cell. 184:3936. PubMed
  230. Acharya A, et al. 2020. J Virol. 95:e01657. PubMed
  231. Audiger C, et al. 2020. J Immunol. 205:121. PubMed
  232. Fernandez-Castaneda A, et al. 2020. Acta Neuropathol. 139:365. PubMed
  233. Köchl R, et al. 2020. Elife. 9:00. PubMed
  234. Honarpisheh P, et al. 2020. J Neuroinflammation. 0.9625. PubMed
  235. OlguÍn-Alor R, et al. 2016. PLoS One. 11:e0167813. PubMed
  236. Crisci E, et al. 2016. J Virol. 90: 4939 - 4950. PubMed
  237. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
  238. Natoli M, et al. 2022. J Immunother Cancer. 10:. PubMed
  239. Wang Z, et al. 2022. Nat Commun. 13:5447. PubMed
  240. Chakraborty A, et al. 2020. Cell Rep. 32:108179. PubMed
  241. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  242. Romine KA, et al. 2021. Blood Cancer Discov. 2:518. PubMed
  243. Romine KA, et al. 2021. Cancer Discov. . PubMed
  244. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  245. Li Y, et al. 2021. Brain Behav Immun. 91:267. PubMed
  246. Kruse S, et al. 2018. Oncoimmunology. 8:e1524694. PubMed
  247. Louveau A, et al. 2018. Curr Protoc Immunol. 121:1. PubMed
  248. Wilmore JR et al. 2018. Cell host & microbe. 23(3):302-311 . PubMed
  249. Joshi N and Werner S. 2017. PLoS One. 10.1371/journal.pone.0187162. PubMed
  250. Zhang F, et al. 2020. EMBO Mol Med. e12034:12. PubMed
  251. Xing J, et al. 2021. Nat Commun. 12:2681. PubMed
  252. Hildebrand KM, et al. 2021. PLoS One. 16:e0253864. PubMed
  253. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  254. Yang Y, et al. 2016. Nucleic Acids Res. 44: 4174 - 4188. PubMed
  255. Coria L, et al. 2016. J Immunol. 196: 4014 - 4029. PubMed
  256. Yamazaki T, et al. 2020. Oncoimmunology. 9:1721810. PubMed
  257. Guo J, et al. 2019. Cancer Immunol Res. 1.349305556. PubMed
  258. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  259. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  260. Hu H, et al. 2021. Cancer Immunol Res. 9:1298. PubMed
  261. Breen EC, et al. 2022. iScience. 25:104488. PubMed
  262. Kallert S, et al. 2017. Nature Communications. 10.1038/ncomms15327. PubMed
  263. Rechtien A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.08.023. PubMed
  264. Giesen D, et al. 2020. Clin Cancer Res. 26:3999. PubMed
  265. Tsang M, et al. 2020. Am J Pathol. 190:206. PubMed
  266. Dieterich LC, et al. 2020. Angiogenesis. 1.24375. PubMed
  267. Brugat T, et al. 2017. Nat Microbiol. 2:16276. PubMed
  268. Andriessen E, et al. 2016. EMBO Mol Med. 8(12):1366-1379. PubMed
  269. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  270. Krämer B, et al. 2016. PLoS One. 11: 0162068. PubMed
  271. Schmid M, et al. 2016. PLoS One. 12: 1005676. PubMed
  272. Contreras F, et al. 2016. J Immunol. 196: 4143 - 4149. PubMed
  273. Larmonier C, et al. 2016. J Biol Chem. 291: 8918-8930. PubMed
  274. Lim X, et al. 2016. Proc Natl Acad Sci U S A. 113: 1498 - 1505. PubMed
  275. Scarneo SA, et al. 2022. Sci Rep. 12:18091. PubMed
  276. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  277. Carmona SJ, et al. 2020. Oncoimmunology. 9:1737369. PubMed
  278. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  279. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  280. Shen J, et al. 2022. Front Immunol. 13:762580. PubMed
  281. Momin N, et al. 2022. Nat Commun. 13:109. PubMed
  282. Haloul M, et al. 2019. Sci Rep. 9:14050. PubMed
  283. Engelbertsen D, et al. 2019. Sci Rep. 9:10608. PubMed
  284. Freire DM, et al. 2019. Mol Cell. 73:1282. PubMed
  285. Coden ME, et al. 2020. J Immunol. 204:438. PubMed
  286. James KR, et al. 2020. Nat Immunol. 1.113194444. PubMed
  287. Lewandowski JP, et al. 2020. Genome Biol. 1.039583333. PubMed
  288. Sabree SA, et al. 2021. J Immunother Cancer. 9: . PubMed
  289. Fu Z, et al. 2021. Nat Commun. 12:4462. PubMed
  290. Pan W, et al. 2021. J Immunol. 206:1719. PubMed
  291. Cohen S, et al. 2015. J Immunol. 194:210. PubMed
  292. Price P, et al. 2015. J Immunol. 194:1164. PubMed
  293. Chattopadhyay A, et al. 2016. J Lipid Res. 57: 832 - 847. PubMed
  294. Dutzan N, et al. 2017. Immunity. 46(1):133-147. PubMed
  295. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  296. Zebertavage LK, et al. 2020. Sci Rep. 10:7376. PubMed
  297. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  298. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  299. Bankova AK, et al. 2022. Transplant Cell Ther. . PubMed
  300. Sinha SR, et al. 2020. Cell Host Microbe. 27:659. PubMed
  301. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
  302. Rossignol J, et al. 2022. iScience. 25:104353. PubMed
  303. Karagianni A, et al. 2022. Front Oncol. 12:929498. PubMed
  304. Castro JT, et al. 2022. Nat Commun. 13:4831. PubMed
  305. Rhys HI, et al. 2018. EBioMedicine. 29:60. PubMed
  306. Fragniere AMC, et al. 2019. Sci Rep. 9:2288. PubMed
  307. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  308. Neal JT, et al. 2018. Cell. 175:1972. PubMed
  309. Jiang Y, et al. 2021. Cell Death Differ. 28:3009. PubMed
  310. Huo Y, et al. 2021. BMC Genomics. 22:145. PubMed
  311. Madsen A, et al. 2020. Immunity. 53:852. PubMed
  312. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  313. Ritzel RM, et al. 2021. Glia. 69:746. PubMed
  314. Parayath NN, et al. 2020. Nat Commun. 4.680555556. PubMed
  315. Wang L, et al. 2020. EMBO J. 39:e104514. PubMed
  316. Ryan P, et al. 2016. Proc Natl Acad Sci U S A. 113(50):14378-14383. PubMed
  317. LM S, et al. 2016. Cell Rep. 16(12): 3286-96. PubMed
  318. Huo Y, et al. 2022. Front Immunol. 13:983116. PubMed
  319. Clark GC, et al. 2022. Front Oncol. 12:913656. PubMed
  320. Xiao L, et al. 2021. Clin Cancer Res. 27:4338. PubMed
  321. Rocha-Resende C, et al. 2021. J Mol Cell Cardiol. 157:98. PubMed
  322. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  323. Barington L, et al. 2022. Cells. 11:. PubMed
  324. Bendtsen SK, et al. 2022. Oncoimmunology. 11:2026020. PubMed
  325. Tron AE, et al. 2018. Nat Commun. 9:5341. PubMed
  326. Collin R, et al. 2017. J Immunol. 10.4049/jimmunol.1600789. PubMed
  327. Teng Y, et al. 2017. J Hematol Oncol. 10.1186/s13045-017-0485-0. PubMed
  328. Yoder A, et al. 2017. PLoS Pathog. 13(2):e1006226. PubMed
  329. Davey M, et al. 2017. Nat Commun. 10.1038/ncomms14760. PubMed
  330. Fang H, et al. 2020. Nat Commun. 4.661805556. PubMed
  331. Hagen SH, et al. 2021. STAR Protocols. 2(3):100641. PubMed
  332. Daemen S, et al. 2021. STAR Protoc. 2:100511. PubMed
  333. Santos NB, et al. 2021. PLoS Pathog. 17:e1009381. PubMed
  334. Schmid M, Harris E 2014. PLoS Pathog. 10:1004541. PubMed
  335. Miller JE, et al. 2021. JCI Insight. 6:. PubMed
  336. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  337. Lee GJ, et al. 2022. Oncoimmunology. 11:2015170. PubMed
  338. Andriessen EMMA, et al. 2021. EMBO Mol Med. 13:e11754. PubMed
  339. Shibata H, et al. 2021. Oncoimmunology. 10:1958589. PubMed
  340. Constant DA, et al. 2022. Immunohorizons. 6:416. PubMed
  341. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  342. Taylor D, et al. 2022. Front Immunol. 13:936129. PubMed
  343. Madsen D, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.12.011. PubMed
  344. Becker JR, et al. 2018. Nat Commun. 9:5406. PubMed
  345. Suan D et al. 2017. Immunity. 47(6):1142-1153 . PubMed
  346. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  347. Nylund P, et al. 2021. Cell Death Dis. 12:167. PubMed
  348. Hofmann J, et al. 2021. Front Immunol. 11:599495. PubMed
  349. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  350. de Winde CM, et al. 2021. J Cell Sci. 134: . PubMed
  351. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  352. Concha-Benavente F, et al. 2016. Cancer Res . 76: 1031 - 1043. PubMed
  353. Li H, et al. 2022. Front Immunol. 13:946202. PubMed
  354. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  355. McCallion A, et al. 2022. Front Immunol. 13:961599. PubMed
  356. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  357. Alice AF, et al. 2021. Sci Rep. 11:16347. PubMed
  358. Singh AK, et al. 2022. Nat Commun. 13:878. PubMed
  359. Kumar S, et al. 2022. Gut. . PubMed
  360. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  361. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  362. Ogrinc Wagner A, et al. 2019. PLoS One. 14:e0210998. PubMed
  363. Zwick M, et al. 2019. Front Immunol. 10:222. PubMed
  364. Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed
  365. Leong Y, et al. 2016. Nat Immunol. 17:1187-1196. PubMed
  366. Ohs I, et al. 2016. Nat Commun. 7:13708. PubMed
  367. Arenas EJ, et al. 2021. Nat Commun. 12:1237. PubMed
  368. Rodriguez E, et al. 2021. Cancers (Basel). 13:. PubMed
  369. Dholakia J, et al. 2022. Gynecol Oncol. 164:170. PubMed
  370. Wegrecki M, et al. 2022. Nat Commun. 13:3872. PubMed
  371. Peng Z, et al. 2022. J Neuroinflammation. 19:186. PubMed
  372. Brockman QR, et al. 2022. JCI Insight. :. PubMed
  373. Lee SH, et al. 2022. Nat Commun. 13:5461. PubMed
  374. Schuldt N, et al. 2017. The Journal of Immunology. 10.4049/jimmunol.1700406. PubMed
  375. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  376. Dawson NA, et al. 2019. JCI Insight. 4:6. PubMed
  377. Vigeland CL, et al. 2019. Physiol Rep. 7:e14019. PubMed
  378. Fucà G, et al. 2021. J Immunother Cancer. 9:. PubMed
  379. Egedal JH, et al. 2021. Mucosal Immunol. 14:1203. PubMed
  380. Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed
  381. Abdelsamed HA, et al. 2020. Nat Immunol. 1.276388889. PubMed
  382. Rocha-Resende C, et al. 2020. JCI Insight. 5:00. PubMed
  383. Luo X, et al. 2020. J Clin Invest. 130:1635. PubMed
  384. Peter Morawski, Chen-Feng Qi, Silvia Boll 2017. Sci Rep. 7:40838. PubMed
  385. Antsiferova M, et al. 2017. EMBO Mol Med. 9(1):27-45. PubMed
  386. Ju X, et al. 2016. J Immunol. 197(12):4613-4625. PubMed
  387. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  388. Gouwy M, et al. 2016. PLoS One. 11:e0166006. PubMed
  389. McGuire V, et al. 2016. Sci Rep. 6:31159. PubMed
  390. Comte D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9321 - 9326. PubMed
  391. Carpenter S, et al. 2016. PLoS Pathog. 12: 1005380. PubMed
  392. Jerby–Arnon L, et al. 2018. Cell. 175:984. PubMed
  393. Pfirschke C, et al. 2020. Cell Rep. 32:108164. PubMed
  394. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  395. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  396. Mello AM, et al. 2022. Oncogenesis. 11:56. PubMed
  397. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  398. Li M, et al. 2021. Mol Biomed. 2:41. PubMed
  399. Milich LM, et al. 2021. J Exp Med. 218:. PubMed
  400. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  401. Neidleman J, et al. 2017. PLoS Pathog. 13(2):e1006163. PubMed
  402. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
  403. Yang C, et al. 2020. Cell Host Microbe. 467:27. PubMed
  404. Blair TC, et al. 2020. J Immunol. 204:3416. PubMed
  405. Martini E, et al. 2016. Cell Rep. 14:1062-1073. PubMed
  406. Weiss G, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.104. PubMed
  407. Dhimolea E, et al. 2021. Cancer Cell. 39:240. PubMed
  408. Li Y, et al. 2022. Theranostics. 12:5364. PubMed
  409. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  410. Patel C, et al. 2022. Curr Protoc. 2:e400. PubMed
  411. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  412. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  413. Salahudeen AA, et al. 2020. bioRxiv. . PubMed
  414. Farooq F, et al. 2016. Sci Rep. 6:27944. PubMed
  415. Tiberti S, et al. 2022. Nat Commun. 13:6752. PubMed
  416. Li Y, et al. 2020. Theranostics. 10:11376. PubMed
  417. Bozoglu T, et al. 2022. Adv Sci (Weinh). 9:e2103867. PubMed
  418. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  419. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  420. Singh SS, et al. 2022. Clin Transl Immunology. 11:e1396. PubMed
  421. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
  422. Verma M, et al. 2021. J Exp Med. 218:. PubMed
  423. Van Winkle JA, et al. 2020. J Virol. 94:. PubMed
  424. Tomlinson JE, et al. 2018. J Neuroinflammation. 0.753472222. PubMed
  425. Padhye A, et al. 2019. Sci Rep. 9:4819. PubMed
  426. Yuan C, et al. 2018. iScience. 11:13. PubMed
  427. Cho SX, et al. 2020. Nat Commun. 4.481944444. PubMed
  428. Filippo Buono M, et al. 2020. Cells. 9:00. PubMed
  429. Friedrich V, et al. 2021. Gut Microbes. 13:1. PubMed
  430. Jiang M, et al. 2021. Front Pharmacol. 12:657486. PubMed
  431. Henkle TR, et al. 2021. Cancer Res. 81:4560. PubMed
  432. Schaller MA, et al. 2021. JCI Insight. 6:e148003. PubMed
  433. Pan L, et al. 2021. Stem Cell Res Ther. 12:496. PubMed
  434. Krogmann A, et al. 2016. PLoS One. 11: 0146326. PubMed
  435. Johns S, et al. 2016. Circ Res . 119: 210 - 221. PubMed
  436. Pflügler S, et al. 2020. Commun Biol. 3:252. PubMed
  437. Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed
  438. Xu L, et al. 2022. Front Immunol. 13:841141. PubMed
  439. Spath S, et al. 2022. iScience. 25:104998. PubMed
  440. Dai H, et al. 2017. J Immunol. 10.4049/jimmunol.1700418. PubMed
  441. Xia L, et al. 2021. Cancer Immunol Res. 9:707. PubMed
  442. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
  443. Schreurs RRCE, et al. 2021. Mucosal Immunology. 14(3):605-614. PubMed
  444. Workel HH, et al. 2020. Int J Mol Sci. 21:00. PubMed
  445. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  446. Salahudeen AA, et al. 2020. Nature. 588:670. PubMed
  447. Hatfield J, Brown M 2015. Cell Immunol. . PubMed
  448. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  449. Wang CJH, et al. 2022. J Biol Chem. :102714. PubMed
  450. Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed
  451. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  452. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  453. Bouchard G, et al. 2022. Cancer Res. 82:648. PubMed
  454. Khurana P, et al. 2021. Front Immunol. 12:700374. PubMed
  455. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  456. Chakraborty A, et al. 2021. Biomaterials. 273:120796. PubMed
  457. Feng Y, et al. 2022. EClinicalMedicine. 43:101226. PubMed
  458. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  459. Tee YC, et al. 2021. FASEB Bioadv. 3:829. PubMed
  460. Orozco SL, et al. 2019. Cell Rep. 28:2275. PubMed
  461. Kimura K, et al. 2018. Nat Commun. 9:17. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

Is Zombie Aqua™ an equivalent to cell labeling and tracer dyes such as CellTrace™ Violet and CFSE?

Zombie Aqua™ is not a direct equivalent to such dyes because their mechanism of action and scope of application are entirely different.

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

Can I use the UV laser to stimulate Zombie Aqua™? If so, can I then use it in conjunction with BV510™?

While we typically do not test Zombie Aqua™ with the UV laser, its excitation peak suggests it is effectively excited at 355 nm. However, we would not recommend using BV510™ off the violet laser and Zombie Aqua™ off the UV laser at the same time. Due to cross-beam excitation of BV510™ by the UV laser and the violet excitation of Zombie Aqua™, this would lead to significantly increased background and excessive compensation requirements.


How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 9    Revision Date: 12/18/2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login/Register
Remember me
Forgot your password? Reset Password
Request an Account